AbbVie and Calibr collaborate to develop T-cell therapies aimed at cancer

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. This collaboration broadens AbbVie’s oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with […]

Genetic subset of prostate cancer may benefit from combination checkpoint immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) released a study investigating the use of combination checkpoint immunotherapy in the treatment of a lethal form of advanced prostate cancer. The study suggested a genetic subset of prostate cancer may benefit from this form of immunotherapy. The study […]

GW Launches New Summer Cancer Research Program for Undergraduate Students

GW Launches New Summer Cancer Research Program for Undergraduate Students The GW-SPARC program is designed to advance cancer research through enhancing diversity Undergraduate students participating in the GW SPARC program June 25, 2018 WASHINGTON (June 25, 2018) —The George Washington University (GW) School of Medicine and Health Sciences, in partnership with the GW Cancer Center, […]

Lund researchers develop fluorescent variant of a molecule that inhibits cancer stem cells

A team of researchers at Lund University in Sweden has developed a fluorescent variant of a molecule that inhibits cancer stem cells. Capturing images of when the molecule enters a cell has enabled the researchers, using cell-biological methods, to successfully describe how and where the molecule counteracts the cancer stem cells. Salinomycin is a molecule […]

AntiCancer’s oral drug overcomes gemcitabine resistance in mouse models of human pancreatic cancer

Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.’s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer’s […]